What is ADMA Biologics's impairment charges?

ADMA Biologics (ADMA) reported impairment charges of $0 in Q1 2026.

What does impairment charges mean?

Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.

ADMA Biologics ADMA Impairment Charges

Impairment Charges at other companies

AmgenAMGN

$0-100%

DanaherDHR

$0-100%

Charles River LaboratoriesCRL

$15.86M+50.0%

HaemoneticsHAE

$77.25M—

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.01B-54.5%

Enterprise value$2.08B-52.5%

P/E12.2×-9.2×

P/S4×-5.7×

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairmentLoss.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's impairment charges?: ADMA Biologics (ADMA) reported impairment charges of $0 in Q1 2026.
What does impairment charges mean?: Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.